Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Portage Biotech Inc ( (PRTG) ).
On January 29, 2025, Portage Biotech Inc. completed a private placement of 524,390 ordinary shares, raising $2.15 million at $4.10 per share. The shares were purchased by two company directors and are intended for use in general corporate purposes and working capital. This financing is expected to support Portage Biotech’s operations and strategic initiatives within the immuno-oncology sector, reflecting a positive impact on their financial stability and ongoing projects.
More about Portage Biotech Inc
Portage Biotech Inc. is a clinical-stage immuno-oncology company that focuses on developing a pipeline of innovative biologics aimed at enhancing the immune system’s capacity to combat cancer.
YTD Price Performance: -9.22%
Average Trading Volume: 673,989
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $5.27M
For an in-depth examination of PRTG stock, go to TipRanks’ Stock Analysis page.
